TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain
Brief Summary: To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to gabapentin.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A
C: Arm Label: Arm I/Group A (Duloxetine then Placebo); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Arm Label: Arm II/Group B (Placebo then Duloxetine); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine)
D: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: pregabalin | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Gabapentin + Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Drug: gabapentin | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine, Gabapentin + Duloxetine | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): Gabapentin + Duloxetine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain
Brief Summary: To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to gabapentin.


Options:
A: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: pregabalin | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Gabapentin + Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Drug: gabapentin | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine, Gabapentin + Duloxetine | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): Gabapentin + Duloxetine
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin Extended Release tablets | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gabapentin Extended Release tablets; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: GEn 1200mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 1200mg/day | Arm Label: GEn 3600mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 3600mg/day | Intervention Type: DRUG; Name: GEn 1200mg/day; Assigned to Arm(s): GEn 1200mg/day | Intervention Type: DRUG; Name: GEn 3600mg/day; Assigned to Arm(s): GEn 3600mg/day
D: Arm Label: Sham-laser acupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham-laser acupuncture | Arm Label: gabapentine; Type: ACTIVE_COMPARATOR; Interventions: Drug: gabapentine | Arm Label: Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture | Intervention Type: DEVICE; Name: Sham-laser acupuncture; Assigned to Arm(s): Sham-laser acupuncture | Intervention Type: DRUG; Name: gabapentine; Assigned to Arm(s): gabapentine | Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): Acupuncture

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis
Brief Summary: The objective of this study is to assess the efficacy and safety of adalimumab for the induction of clinical remission in subjects with moderately to severely active ulcerative colitis.


Options:
A: Arm Label: Adalimumab 80/40; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 160/80/40; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80/40 | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160/80/40 | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Golimumab 100 mg -> 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 50 mg | Arm Label: Golimumab 200 mg -> 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Golimumab 400 mg -> 200 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 200 mg, Biological: Golimumab 400 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg, Golimumab 200 mg -> 100 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): Golimumab 200 mg -> 100 mg, Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 400 mg; Assigned to Arm(s): Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg
C: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: rhuMAb Beta7; Type: EXPERIMENTAL; Interventions: Drug: rhuMAb Beta7 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: rhuMAb Beta7; Assigned to Arm(s): rhuMAb Beta7

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis
Brief Summary: The objective of this study is to assess the efficacy and safety of adalimumab for the induction of clinical remission in subjects with moderately to severely active ulcerative colitis.


Options:
A: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
B: Arm Label: 1 (i); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: 2 (ii); Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 (i), 2 (ii)
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Golimumab 100 mg -> 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 50 mg | Arm Label: Golimumab 200 mg -> 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Golimumab 400 mg -> 200 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 200 mg, Biological: Golimumab 400 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg, Golimumab 200 mg -> 100 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): Golimumab 200 mg -> 100 mg, Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 400 mg; Assigned to Arm(s): Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg
D: Arm Label: Adalimumab 80/40; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 160/80/40; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80/40 | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160/80/40 | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Aging on the Isolated Pituitary Response to Gonadotropin Releasing Hormone at Baseline and With Low Dose Estrogen Administration
Brief Summary: The purpose of this study is to study the effects of aging and estrogen on the brain. Specifically, this study will examine how the hypothalamus signals the pituitary gland to secrete reproductive hormones and how that changes with aging.


Options:
A: Arm Label: Young postmenopausal women; Type: EXPERIMENTAL; Interventions: Drug: GnRH, Drug: NAL-GLU GnRH antagonist, Drug: Estrogen patch | Arm Label: Older postmenopausal women; Type: EXPERIMENTAL; Interventions: Drug: GnRH, Drug: NAL-GLU GnRH antagonist, Drug: Estrogen patch | Intervention Type: DRUG; Name: GnRH; Assigned to Arm(s): Older postmenopausal women, Young postmenopausal women | Intervention Type: DRUG; Name: NAL-GLU GnRH antagonist; Assigned to Arm(s): Older postmenopausal women, Young postmenopausal women | Intervention Type: DRUG; Name: Estrogen patch; Assigned to Arm(s): Older postmenopausal women, Young postmenopausal women
B: Arm Label: Biopsy catheter; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial biopsy | Intervention Type: PROCEDURE; Name: Endometrial biopsy; Assigned to Arm(s): Biopsy catheter | Intervention Type: PROCEDURE; Name: Endometrial Biopsy; Assigned to Arm(s): Biopsy catheter
C: Intervention Type: PROCEDURE; Name: Endometrial biopsy; Assigned to Arm(s): N/A
D: Arm Label: experimental; Type: EXPERIMENTAL; Interventions: Drug: crinone (progesterone 8%, vaginal application) | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: crinone (progesterone 8%, vaginal application); Assigned to Arm(s): experimental

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety of SR141716 in Obese Patients With or Without Comorbidities (RIO-Europe)
Brief Summary: The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities.

The main secondary objectives were to assess the effect of SR141716 on lipid parameters (HDL-C, TG), glucose tolerance status, the rate of patients with metabolic syndrome, waist circumference, glycemic parameters.


Options:
A: Arm Label: Lorcaserin plus Lifestyle Modification; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorcaserin | Arm Label: Placebo plus Lifestyle Modification; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lorcaserin; Assigned to Arm(s): Lorcaserin plus Lifestyle Modification | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus Lifestyle Modification
B: Intervention Type: DRUG; Name: rimonabant (SR141716); Assigned to Arm(s): N/A
C: Arm Label: Lorcaserin 10 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg once daily (QD) | Arm Label: Lorcaserin 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg twice a day (BID) | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo | Intervention Type: DRUG; Name: Lorcaserin 10 mg once daily (QD); Assigned to Arm(s): Lorcaserin 10 mg QD | Intervention Type: DRUG; Name: Lorcaserin 10 mg twice a day (BID); Assigned to Arm(s): Lorcaserin 10 mg BID | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo
D: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Iron Fortified Whole Maize Flour on the Iron Status of School Children in Kenya
Brief Summary: The purpose of this study is to assess whether NaFeEDTA and electrolytic iron improve iron status of young school children, when added as iron fortificants in whole maize flour.


Options:
A: Intervention Type: DRUG; Name: NaFeEDTA, Electrolytic Iron; Assigned to Arm(s): N/A
B: Arm Label: Maize porridge with Amaranth; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Maize and Amaranth | Arm Label: Maize flour with multiple micronutrients; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Maize and Amaranth | Arm Label: Maize Porridge; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maize and Amaranth | Intervention Type: DIETARY_SUPPLEMENT; Name: Maize and Amaranth; Assigned to Arm(s): Maize Porridge, Maize flour with multiple micronutrients, Maize porridge with Amaranth
C: Arm Label: Dietary supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Corn Soya Blend+ | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn Soya Blend+; Assigned to Arm(s): Dietary supplement
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial to Assess the Effects of Iron Supplementation in Heart Failure Patients With Anemia: The IRON-HF Study
Brief Summary: Anemia has been demonstrated to be a common finding in patients with heart failure (HF). Previous studies in hospitalized patients with HF have found a prevalence of anemia ranging from 15% to 63%. More importantly, anemic patients with HF have increased morbidity and mortality. The mechanisms underlying anemia in HF are multifactorial, involving mild to moderate forms of anemia of chronic disease and ferropenic anemia. The clinical impact of iron supplementation in HF patients who have a relatively preserved renal function and either chronic disease anemia, ferropenic anemia or both remains largely unknown. The route of iron administration that could be most clinically effective is also unclear. Thus, the primary aim of the IRON-HF study is to assess the effects of iron supplementation alone (IV or PO) on parameters of functional capacity in HF patients with anemia with decreased availability of iron.


Options:
A: Intervention Type: DRUG; Name: Venofer (intravenous iron sucrose); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Iron Sucrose IV 200mg, once a week, for 5 weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ferrous sulfate 200mg PO TID, for 8 weeks; Assigned to Arm(s): N/A
C: Arm Label: Ferinject (ferric carboxymaltose); Type: EXPERIMENTAL; Interventions: Drug: Ferinject (ferric carboxymaltose) | Arm Label: Placebo (saline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (saline) | Intervention Type: DRUG; Name: Ferinject (ferric carboxymaltose); Assigned to Arm(s): Ferinject (ferric carboxymaltose) | Intervention Type: DRUG; Name: Placebo (saline); Assigned to Arm(s): Placebo (saline)
D: Arm Label: Iron Dextran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Iron dextran | Arm Label: Iron Sucrose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Iron sucrose | Intervention Type: DRUG; Name: Iron dextran; Assigned to Arm(s): Iron Dextran | Intervention Type: DRUG; Name: Iron sucrose; Assigned to Arm(s): Iron Sucrose

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial to Assess the Effects of Iron Supplementation in Heart Failure Patients With Anemia: The IRON-HF Study
Brief Summary: Anemia has been demonstrated to be a common finding in patients with heart failure (HF). Previous studies in hospitalized patients with HF have found a prevalence of anemia ranging from 15% to 63%. More importantly, anemic patients with HF have increased morbidity and mortality. The mechanisms underlying anemia in HF are multifactorial, involving mild to moderate forms of anemia of chronic disease and ferropenic anemia. The clinical impact of iron supplementation in HF patients who have a relatively preserved renal function and either chronic disease anemia, ferropenic anemia or both remains largely unknown. The route of iron administration that could be most clinically effective is also unclear. Thus, the primary aim of the IRON-HF study is to assess the effects of iron supplementation alone (IV or PO) on parameters of functional capacity in HF patients with anemia with decreased availability of iron.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FE; Type: EXPERIMENTAL; Interventions: Drug: Ferric carboxymaltose | Arm Label: EPOFE; Type: EXPERIMENTAL; Interventions: Drug: Ferric carboxymaltose, Drug: Erythropoietin | Intervention Type: DRUG; Name: Ferric carboxymaltose; Assigned to Arm(s): EPOFE, FE | Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): EPOFE | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Iron Sucrose IV 200mg, once a week, for 5 weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ferrous sulfate 200mg PO TID, for 8 weeks; Assigned to Arm(s): N/A
C: Arm Label: Ferric Carboxymaltose (FCM); Type: EXPERIMENTAL; Interventions: Drug: Ferric Carboxymaltose (FCM) | Arm Label: Ferrous Sulfate tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ferrous Sulfate tablets | Intervention Type: DRUG; Name: Ferric Carboxymaltose (FCM); Assigned to Arm(s): Ferric Carboxymaltose (FCM) | Intervention Type: DRUG; Name: Ferrous Sulfate tablets; Assigned to Arm(s): Ferrous Sulfate tablets
D: Arm Label: IV trivalent saccharose hydroxide ferrous; Type: EXPERIMENTAL; Interventions: Drug: IV trivalent saccharose hydroxide ferrous | Arm Label: Oral ferrous fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral ferrous fumarate | Arm Label: Oral and intravenous Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oral and intravenous Placebo | Intervention Type: DRUG; Name: IV trivalent saccharose hydroxide ferrous; Assigned to Arm(s): IV trivalent saccharose hydroxide ferrous | Intervention Type: DRUG; Name: Oral ferrous fumarate; Assigned to Arm(s): Oral ferrous fumarate | Intervention Type: DRUG; Name: Oral and intravenous Placebo; Assigned to Arm(s): Oral and intravenous Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study To Evaluate Efficacy and Safety of XP12B for the Treatment of Menorrhagia
Brief Summary: The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.


Options:
A: Arm Label: Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours; Type: EXPERIMENTAL; Interventions: Drug: Levonorgestrel IUS (Mirena, BAY86-5028) | Arm Label: Medroxyprogesterone acetate (MPA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Medroxyprogesterone acetate | Intervention Type: DRUG; Name: Levonorgestrel IUS (Mirena, BAY86-5028); Assigned to Arm(s): Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours | Intervention Type: DRUG; Name: Medroxyprogesterone acetate; Assigned to Arm(s): Medroxyprogesterone acetate (MPA)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid tablets | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablets | Intervention Type: DRUG; Name: Tranexamic acid tablets; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): 2
C: Arm Label: novasure; Type: ACTIVE_COMPARATOR; Interventions: Device: NovaSure | Arm Label: thermachoice; Type: OTHER; Interventions: Device: thermachoice | Intervention Type: DEVICE; Name: NovaSure; Assigned to Arm(s): novasure | Intervention Type: DEVICE; Name: thermachoice; Assigned to Arm(s): thermachoice
D: Intervention Type: PROCEDURE; Name: hysterectomy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: endometrial ablation; Assigned to Arm(s): N/A

Answer: B